Playground Global led the Series A round to support the firm in achieving practical quantum advantage.
"For all the advances that have been made in quantum hardware, and for all quantum computing’s promise, such progress could end up being for nothing if we can’t build the applications needed to make the technology truly useful. With our record-breaking algorithms and groundbreaking techniques, we are pushing the boundaries of what is possible in this space. With support from such a renowned deep-tech visionary as Playground, we think practical quantum advantage is achievable in years, not decades."
The funding round was led by SFC Capital and OION to prepare the medical device startup for patient trials.
"A younger patient has about a 35% chance of implant failure during their lifetime, and the leading cause of failure is loss of fixation between the bone and the implant"
Parkwalk Advisors led the financing round, which will support UK sales growth and international expansion plans.
"For scaling companies, keeping track of terms across hundreds or thousands of contracts is a challenge that creeps up on you. Searching for basic information like contract start and end dates, or nuances in confidentiality terms across entire databases of contracts is painfully manual, or impossible. Before working with us, we know that some of our customers would spend weeks doing this"
The oversubscribed round was led by Bosch Ventures with backing from Porsche SE and British Patient Capital.
"The support of leading technology investors enables us to realise our vision of a quantum computer built using standard foundry processes. This support, along with the continuing UK national quantum programme and European initiatives, provides a step-change in our capabilities. We have assembled a world leading team and with the funding and support in place, we are ready to scale and deliver on our vision."
The oversubscribed round will scale up manufacturing and research for the bioactive protein developer.
"We are at an exciting stage of development, with new funds facilitating our next phase of rapid growth as we continue our mission of providing more reliable tools for research and bio-manufacturing. Our platform provides an improved process for complex protein manufacture at exceptionally high purity and unique engineered products that address specific challenges for stem cell biology. Growth factors are essential reagents for all stem cell manufacturing, and therefore critical for the delivery of cell therapies and cultivated meats."
.png)
